Recent 8-K filings for TOI

• May 22, 2026 20:30 UTC cyber materiality 0.70 negative item 1.05item 7.01item 9.01

  Oncology Institute patient data accessed in Vendor cybersecurity incident; operations sustained

  On May 20, 2026, Kroll notified TOI that its Vendor detected unauthorized access to TOI patient data systems.

• May 07, 2026 23:59 UTC earnings materiality 0.65 positive item 2.02item 9.01

  TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M

  Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.

• Mar 12, 2026 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M

  Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).

• Jan 12, 2026 23:59 UTC other material materiality 0.70 positive item 2.02item 9.01

  TOI reaffirms 2025 guidance, provides 2026 outlook: rev $630M-$650M, first full yr positive Adj EBITDA

  2026 revenue guidance $630M-$650M, ~28% growth from 2025 midpoint.

• Nov 13, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02item 9.01

  TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance

  Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.

• Aug 13, 2025 23:59 UTC earnings materiality 0.70 positive item 2.02item 9.01

  TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance

  Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.

• May 14, 2025 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance

  Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.

• May 08, 2025 23:59 UTC other material materiality 0.65 neutral item 5.07

  TOI shareholders approve reverse stock split up to 1:40; re-elect all 8 directors

  Reverse stock split approved at ratio between 1:5 and 1:40, board discretion within one year.

• Mar 27, 2025 23:59 UTC other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  The Oncology Institute closes ~$16.4M private placement and $4.1M note exchange

  Private placement of 12.0M shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.

• Mar 25, 2025 23:59 UTC other material materiality 0.65 neutral item 1.01item 3.02item 3.03item 5.03item 7.01item 9.01

  The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes

  Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.

• Mar 24, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M

  Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.

• Feb 26, 2025 23:59 UTC debt materiality 0.70 positive item 1.01item 7.01item 9.01

  TOI amends Deerfield credit agreement, removes $40M cash covenant, pays down $20M notes

  Deerfield waived restrictions on equity issuance and removed the $40M minimum cash covenant.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event other_material

5 positive 2 negative 16 neutral

source · TOI on sec.gov